Eledon Pharmaceuticals
ELDN
10 hedge funds and large institutions have $2.82M invested in Eledon Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0.29% less ownership
Funds ownership: 2.38% → 2.08% (-0.29%)
18% less capital invested
Capital invested by funds: $3.45M → $2.82M (-$631K)
33% less funds holding
Funds holding: 15 → 10 (-5)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$43.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$201K |
| 2 |
6CM
683 Capital Management
New York
|
-$190K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$38K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$14.8K |
| 5 |
VF
Virtu Financial
New York
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $1.85M | – | – | – |
|
|
BI
2
BVF Inc
San Francisco,
California
| $481K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $264K | +$43.3K | +4,084 | +19% |
|
|
6CM
4
683 Capital Management
New York
| $174K | -$190K | -17,950 | -52% |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $22K | -$14.8K | -1,393 | -40% |
|
6
BlackRock
New York
| $19K | -$148 | -14 | -0.8% |
|
7
Geode Capital Management
Boston,
Massachusetts
| $7K | – | – | – |
|
8
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | -$4.53K | -428 | -65% |
|
|
9
UBS Group
Zurich,
Switzerland
| $2K | +$2.18K | +206 | New |
|
|
BC
10
Boxer Capital
San Diego,
California
| – | -$201K | -18,021 | Closed |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$38K | -3,365 | Closed |
|
|
VF
12
Virtu Financial
New York
| – | -$9K | -784 | Closed |
|
|
HR
13
Hayden Royal
Charlotte,
North Carolina
| – | -$6K | -556 | Closed |
|
14
Victory Capital Management
San Antonio,
Texas
| – | -$1K | -117 | Closed |
|
ELDN Hedge Fund Activity: Q4 2019 in Review
10 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2019, worth a combined $2.82M — down 18% from $3.45M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELDN and 1 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $43.3K. The largest seller was Boxer Capital, exiting entirely with an estimated $201K sold.
- 10 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2019, down from 15 in Q3 2019.
- Funds reported $2.82M of Eledon Pharmaceuticals stock for Q4 2019, down 18% quarter-over-quarter.
- 1 fund opened new Eledon Pharmaceuticals positions in Q4 2019 and 6 closed out, a net change of -5 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2019 was Renaissance Technologies, an estimated $43.3K added.
- The largest Eledon Pharmaceuticals seller in Q4 2019 was Boxer Capital, an estimated $201K sold.
Based on aggregated 13F filings for Q4 2019.